SS Innovations International, Inc. (NASDAQ: SSII) has been named Outstanding Company at the 2026 Surgical Robotics Industry Awards, surpassing finalists including Intuitive Surgical (NASDAQ: ISRG), Johnson & Johnson (NYSE: JNJ), and Medtronic (NYSE: MDT). The award recognizes a single company demonstrating excellence in innovation, commercial success, industry leadership and positive societal impact.
The recognition places SS Innovations ahead of some of the largest names in medical technology and surgical robotics. The award is particularly significant given the competitive landscape, with finalists also including MicroPort Scientific, Distalmotion, FUTEK, Meril, Precision IO Group, and THINK Surgical. The Surgical Robotics Industry Awards honor companies that are driving advancements in the field and making a tangible difference in patient care.
SS Innovations is known for developing the SSi Mantra surgical robotic system and the SSi Mudra suite of surgical instruments, which support a variety of procedures including cardiac surgery. The company’s mission is to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. Headquartered in India but incorporated in the United States, SS Innovations plans to expand the global presence of its cost-effective and user-friendly robotic solutions.
The award underscores the company’s growing influence in the surgical robotics market, which has traditionally been dominated by Intuitive Surgical’s da Vinci system. By focusing on affordability and accessibility, SS Innovations is positioning itself as a disruptive force that could expand robotic surgery to underserved markets. For more information about SS Innovations, visit their newsroom at https://ibn.fm/SSII.
The news comes as the global surgical robotics market is projected to grow significantly, driven by technological advancements and increasing demand for minimally invasive procedures. SS Innovations’ recognition as Outstanding Company suggests that the industry sees potential in its approach to democratizing robotic surgery. However, the company still faces challenges in scaling production, gaining regulatory approvals in new markets, and competing with established players.
